CompletedNot Applicable

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

United States121 participantsStarted 2010-02

Plain-language summary

The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome. Subjects were also randomized to either an Extended Treatment Group (ETG) defined by receiving comprehensive medication management (CMM) pharmacist interventions or a Usual Treatment Group (UTG) receiving no CMM interventions. All subjects were recruited from three community mental health clinic settings in Minnesota.

Who can participate

Age range18 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * English speaking * Age 18-64 * Competent to understand and make medical choices independently Exclusion Criteria: * Currently or previously seen by a CMM pharmacist

What they're measuring

Metabolic Syndrome (MetS)

Timeframe: Baseline

Trial details

NCT IDNCT02029989

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-02

Results submitted2014-04-15

View on ClinicalTrials.gov More Hyperlipidemia trials